LIFESCIENCE REAGENT MARKET ANALYSIS

Lifescience Reagent MarketSize and Trends

Increasing prevalence of infectious disease, which requires early diagnosis is creating the opportunity for the biotechnology industry players to produce effective reagents to carry out various diagnostic tests. Moreover, launching of new diagnostic tests and assays is contributing to the lifescience reagents market share. For instance, in April 2019, Roche launched Ventana HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer patients to determine the eligibility for the targeted drug trastuzumab (Herceptin). The new reagent is intended for in vitro diagnostic (IVD) use.

The global lifescience reagent market was valued at US$ 33,754.0 million in 2017, and is expected to witness a CAGR of 7.3% during the forecast period (2018–2026).

Figure 1. Global Lifescience Reagent Market value Analysis (US$ Mn) and Forecast and Absolute $ Opportunity

Source: Coherent Market Insights Analysis (2019)

Increasing number of product launches is expected to drive growth of global lifescience reagent market

Increasing product launches for reagents to assist different types of diagnostics tests and research purpose is expected to drive the global lifescience reagent market growth. For instance, in March 2019, Dolomite Bio, a provider of single cell technologies, launched a new scRNA-Seq reagent kit to expand the Nadia Instrument portfolio. The new scRNA-Seq reagent kit is designed to enable the generation of PCR­amplified cDNA libraries on the Nadia Instrument, allowing high throughput gene expression profiling of heterogeneous cell populations.

Moreover, in October 2016, Beckman Coulter’s lifescience division launched Clearllab LS Lymphoid Screen Reagent. It is CE-marked and 10-colour containing 12 antibody reagent combinations used for leukemia and lymphoma analysis. The new approach is designed to provide results with a faster turnaround time (TAT). ClearLLab has been specifically designed for identification of haematolymphoid cells on the Beckman Coulter’s Navios flow cytometer.

Increasing acquisitions among biotechnology industry players is contributing to the global lifescience reagent market during the forecast period. For instance, in February 2017, Anatrace (StoneCalibre’s portfolio company), acquired Molecular Dimensions Ltd. Molecular Dimensions Ltd is the U.K.-based supplier of modern screens, reagents, and other consumables and instrumentation for structural biology research. With this acquisition, Anatrace intended to establish its presence in Europe and expand its position in the structural biology product portfolio.